Dr Reddys Laboratories Ltd (DRREDDY) — shareholding pattern, promoter holding, financials and share price
About Dr Reddys Laboratories Ltd (DRREDDY)
Dr Reddys Laboratories Ltd operates in the Pharmaceuticals industry, within the Healthcare sector. It trades on the NSE as DRREDDY and on the BSE under scrip code 500124. Its ISIN is INE089A01031.
Dr. Reddy's Laboratories Ltd is a leading India-based pharmaceutical company which offers a portfolio of products and services, including Active Pharmaceutical Ingredients (APIs), Custom Pharmaceutical services (CPS), generics, biosimilars and differentiated formulations.
Dr. Reddy's Laboratories is a global pharmaceutical company headquartered in Hyderabad, India. It focuses on providing affordable and innovative medicines across major therapeutic areas such as oncology, gastrointestinal, and cardiovascular.
The company demonstrated a 4.4% year-on-year revenue growth in Q3FY26, despite facing headwinds from lower sales in certain product lines like Lenalidomide, showcasing its underlying business strength.
Listed peers in Pharmaceuticals: Cipla Ltd, Zydus Lifesciences Ltd, Lupin Ltd, Mankind Pharma Ltd, Aurobindo Pharma Ltd, Laurus Labs Ltd.
Valuation & Returns
10 Jul 2026At ₹1,245.5 a share on 10 Jul 2026, Dr Reddys Laboratories Ltd (DRREDDY) was valued at a price-to-earnings ratio of 25x against an industry P/E of 36.41x and a price-to-book of 2.74x on a book value of ₹453.97 per share as of Mar 2026. Solomo computes return on equity of 10.97% and return on capital employed of 12.64% from filed results. Earnings ratios use consolidated results for the twelve months Jun 2025 to Mar 2026.
- P/E
- 25x
- Industry P/E
- 36.41x
- P/B
- 2.74x
- EPS (TTM)
- ₹49.81
- Book value / share
- ₹453.97
- ROE
- 10.97%
- ROCE
- 12.64%
- ROA
- 7.15%
- Debt / equity
- 0.2x
- Dividend yield
- 1.28%
- EBITDA margin
- 23.29%
- 52-week range
- ₹1,149 – ₹1,414.4
Ratios are computed from filed results and the last recorded price. Not investment advice.
Financial Performance
Mar 2026In the year ended Mar 2026, Dr Reddys Laboratories Ltd (DRREDDY) reported revenue of ₹33,700 crore, net profit of ₹4,158 crore and earnings per share of ₹50.27. That compares with revenue of ₹32,644 crore and net profit of ₹5,725 crore in Mar 2025. Figures are consolidated, as filed with the exchanges.
In the quarter ended Mar 2026, revenue was ₹7,546 crore and net profit ₹221 crore (consolidated).
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue (₹ cr) | 21,545 | 24,670 | 28,011 | 32,644 | 33,700 |
| Net profit (₹ cr) | 2,182 | 4,507 | 5,578 | 5,725 | 4,158 |
| EPS (₹) | 26.23 | 54.14 | 66.87 | 67.77 | 50.27 |
| Measure | 10Y | 5Y | 3Y | 1Y |
|---|---|---|---|---|
| Sales growth | 8.66% | 8.99% | 6.57% | 3.24% |
| Profit growth | 9.83% | 8.05% | 7.21% | -27.38% |
| Stock price CAGR | 6% | 3% | 5% | -3% |
Ownership Summary
Jun 2026As of Jun 2026, promoters hold 26.64% of Dr Reddys Laboratories Ltd (DRREDDY) (up 0.01 pp QoQ), foreign institutional investors (FII) hold 32.07% and domestic institutional investors (DII) hold 31.74%. Market capitalisation was ₹1,03,959 crore on 10 Jul 2026. Shareholding is filed quarterly with BSE and NSE; Solomo carries every filing back to Mar 2001.
Largest disclosed public shareholders in Jun 2026: LIFE INSURANCE CORPORATION OF INDIA P & GS FUND 12.16%, J P Morgan Chase Bank NA 11.41%, ICICI PRUDENTIAL VALUE DISCOVERY FUND 4.41%, NPS TRUST-A/C SBI PENSION FUND SCHEME TAX SAVER-TIER 2 3.15%, NIPPON LIFE INDIA TRUSTEE LTD-A/C-NIPPON INDIA NIFTY 50 VALUE 20 INDEX FUND 1.88%, PARAG PARIKH FLEXI CAP FUND 1.76%. Only stakes above the 1% disclosure threshold are named in filings.
| Quarter | Promoter | Pledged | FII | DII | Public |
|---|---|---|---|---|---|
| Jun 2026 | 26.64% | - | 32.07% | 31.74% | 73.16% |
| Mar 2026 | 26.63% | - | 33.08% | 30.72% | 73.13% |
| Dec 2025 | 26.64% | - | 33.2% | 30.44% | 73.12% |
| Sep 2025 | 26.64% | - | 35.52% | 27.98% | 73.11% |
| Jun 2025 | 26.64% | - | 36.36% | 26.74% | 73.1% |
| Mar 2025 | 26.64% | - | 37.29% | 25.62% | 73.07% |
| Dec 2024 | 26.64% | - | 40.08% | 22.9% | 73.2% |
| Sep 2024 | 26.64% | - | 41.75% | 21.48% | 73.2% |